Autism is a serious developmental disease that lasts a lifetime. The rates of autism continue to rise, the cause of the disease remains unknown and there is no cure. We believe that children on the autism spectrum can lead fulfilling and productive lives. That is why JelikaLite is developing Cognilum, an integrative solution with focus on pediatric neurological health using non-invasive novel therapies. Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care. Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.
Location: United States, New York
Employees: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Bioverge | ventures.b... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 01.02.2023 | JelikaLite Announces Positive Results From a New Feasibility... | Pilot study data suggests that JelikaLite’s Cognilum medical device reduces symptoms of autism in yo... | venturebea... |
| 06.01.2022 | FDA Grants Breakthrough Device Designation to JelikaLite | Pilot study data suggests that JelikaLite’s Cognium medical device reduces symptoms of autism in you... | venturebea... |
| 06.01.2022 | FDA Grants Breakthrough Device Designation to JelikaLite | JelikaLite Corp, a medical technology company, announced today that the U.S. Food and Drug Administr... | marketscre... |